NCT06128304 (ACCESS) is a NA clinical trial of Core Implementation strategies in HIV, sponsored by University of California, San Diego.

Who is sponsoring NCT06128304?

NCT06128304 is sponsored by University of California, San Diego.

What drugs are being tested in NCT06128304?

Interventions in NCT06128304: Core Implementation strategies, Core+ Enhanced Implementation Strategies.

What condition does NCT06128304 study?

NCT06128304 studies HIV, Cervical Cancer.

Is NCT06128304 still recruiting?

NCT06128304 is currently recruiting now. Last updated 10 February 2026.

Last reviewed 2026-02-10 · How we verify

NCT06128304: ACCESS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services

Recruiting now NA Last updated 10 February 2026

What this trial tests

NA trial testing Core Implementation strategies in HIV in 2,436 participants. Currently enrolling.

Timeline

13 November 2023

Primary endpoint
1 December 2026

31 August 2027

Quick facts

Lead sponsor	University of California, San Diego
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	2,436
Start date	13 November 2023
Primary completion	1 December 2026
Estimated completion	31 August 2027
Sites	2 locations across United States, Nigeria

Drugs / interventions tested

Core Implementation strategies
Core+ Enhanced Implementation Strategies

Conditions studied

HIV — all drugs for HIV →
Cervical Cancer — all drugs for Cervical Cancer →

Sponsor

University of California, San Diego

Who can join

Adults 25 to 64, female only, with HIV or Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

While there has been a significant increase in the uptake of antiretroviral therapy among women living with HIV (WLHIV) in many low- and-middle income countries (LMICs), the coverage of cervical cancer screening and treatment (CCST) among WLHIV remains low. This study aims to leverage the available infrastructure for HIV care and treatment programs in Nigeria to integrate cervical cancer screening and treatment and conduct a cluster randomized, hybrid type III trial design to assess the comparative effectiveness of a Core set of implementation strategies versus a Core+ (enhanced) set of implementation strategies to implement cervical cancer screening, onsite treatment, referral and referral completion, treatment, and retention in care among WLHIV. The overarching goal is to improve the health and life expectancy of WLHIV with co-occurring cervical cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Comparative effectiveness of implementation strategies for Accelerating Cervical Cancer Elimination through the integration of Screen-and-treat Services (ACCESS study): protocol for a cluster randomized hybrid type III trial in Nigeria.
Olakunde BO, Itanyi IU, Olawepo JO, Liu L, et al · · 2024 · cited 2× · PMID 38468266 · DOI 10.1186/s13012-024-01349-9

Verify or expand the search:

Other recruiting trials for HIV

Currently open trials in the same condition.

NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT07221214 — GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · recruiting
NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV · NA · recruiting
NCT07390474 — Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA i · Phase 1 · recruiting
NCT07390955 — A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 · Phase 1 · recruiting

Other University of California, San Diego trials

Trials by the same sponsor.

NCT07342543 — Guided Physical Activity Counseling for Hypertension in Primary Care · NA · not yet recruiting
NCT06505317 — Artificial Intelligence for Early Detection of Peripheral Artery Disease · NA · not yet recruiting
NCT07211802 — CKM For Safe Use of SGLT2i in Type 1 Diabetes · Phase 3 · not yet recruiting
NCT07524751 — Culturally Adapted Pain Management for Indigenous Peoples · NA · not yet recruiting
NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2) · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06128304 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Diego
Last refreshed: 10 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06128304.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing